These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 878015)

  • 21. Determination of the acetylator phenotype in Moroccan tuberculosis patients using isoniazid as metabolic probe.
    Aït Moussa L; Khassouani CE; Hüe B; Jana M; Bégaud B; Soulaymani R
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):548-53. PubMed ID: 12503812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.
    Donald PR; Parkin DP; Seifart HI; Schaaf HS; van Helden PD; Werely CJ; Sirgel FA; Venter A; Maritz JS
    Eur J Clin Pharmacol; 2007 Jul; 63(7):633-9. PubMed ID: 17505821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
    Ellard GA
    Cas Lek Cesk; 1984 Feb; 123(6):158-64. PubMed ID: 6697364
    [No Abstract]   [Full Text] [Related]  

  • 24. Incidence of isoniazid acetylation phenotypes in North Indians.
    Gupta RC; Nair CR; Jindal SK; Malik SK
    Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):259-64. PubMed ID: 6746149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Isoniazid acetylation in a group of Tunisian patients. Report of 620 patients].
    Mehiri BR; Zouaoui A; Chérif J; Ourari B; Daghfous R; Oueslati MH; Louzir B; Daghfous J; Chelbi B; Béji M
    Tunis Med; 2005 Jul; 83(7):385-9. PubMed ID: 16220693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics of isoniazid.
    Weber WW; Hein DW
    Clin Pharmacokinet; 1979; 4(6):401-22. PubMed ID: 391461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isoniazid acetylation rates (phenotypes) of patients being treated for tuberculosis.
    Mason E; Russell DW
    Bull World Health Organ; 1971; 45(5):617-24. PubMed ID: 5316954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isoniazid acetylator status of Black South African tuberculosis patients.
    Bach PH; Higgins-Opitz SB; Bima B; Leary WP
    S Afr Med J; 1976 Jul; 50(29):1132-4. PubMed ID: 959925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population screening for isoniazid acetylator phenotype.
    Seifart HI; Parkin DP; Botha FJ; Donald PR; Van Der Walt BJ
    Pharmacoepidemiol Drug Saf; 2001; 10(2):127-34. PubMed ID: 11499851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenotyping of South African black tuberculosis patients for inactivation of isoniazid.
    Eidus L; Glatthaar E; Hodgkin MM; Nel EE; Kleeberg HH
    Res Commun Chem Pathol Pharmacol; 1979 Feb; 23(2):243-56. PubMed ID: 461951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acetylator phenotype and metabolic disposition of isoniazid in Japanese patients with systemic lupus erythematosus.
    Ishizaki T; Horai Y; Koya G; Matsuyama K; Iguchi S
    Arthritis Rheum; 1981 Oct; 24(10):1245-54. PubMed ID: 7306226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid.
    Donald PR; Sirgel FA; Venter A; Parkin DP; Seifart HI; van de Wal BW; Werely C; van Helden PD; Maritz JS
    Clin Infect Dis; 2004 Nov; 39(10):1425-30. PubMed ID: 15546075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phenotypic interaction of simultaneously administered isoniazid and phenytoin in patients with tuberculous meningitis or tuberculoma having seizures.
    Adole PS; Singh A; Kharbanda PS; Sharma S
    Eur J Pharmacol; 2013 Aug; 714(1-3):157-62. PubMed ID: 23792142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of coadministration of procainamide and isoniazid on each other's acetylation pathway.
    Schneck DW; Sprouse JS; Shiroff RA; Vary JE; DeWitt FO; Hayes AH
    Pharmacology; 1979; 18(1):34-41. PubMed ID: 419159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of various isoniazid slow releasing matrix preparations for intermittent chemotherapy of tuberculosis.
    Hodgkin MM; Eidus L; Hershfield ES
    Res Commun Chem Pathol Pharmacol; 1979 May; 24(2):349-65. PubMed ID: 461989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classification of children as slow or rapid acetylators based on concentrations of isoniazid in saliva following oral administration of body-weight and surface-area-related dosages of the drug.
    Sarma GR; Kailasam S; Datta M; Loganathan GK; Rahman F; Narayana AS
    Indian Pediatr; 1990 Feb; 27(2):134-42. PubMed ID: 2361757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype.
    Yamamoto T; Suou T; Hirayama C
    Hepatology; 1986; 6(2):295-8. PubMed ID: 3957235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients.
    Gent WL; Seifart HI; Parkin DP; Donald PR; Lamprecht JH
    Eur J Clin Pharmacol; 1992; 43(2):131-6. PubMed ID: 1425868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A single sample saliva test to determine acetylator phenotype.
    Hutchings AD; Routledge PA
    Br J Clin Pharmacol; 1996 Nov; 42(5):635-7. PubMed ID: 8951197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between serum isonicotinic acid hydrazide (INH) levels and urinary sulfadimidine (sulfamethazine) acetylation as predictors of INH acetylator status.
    Seth V; Seth SD; Beotra A; Singh U
    Dev Pharmacol Ther; 1988; 11(1):32-6. PubMed ID: 3383719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.